TICKERNERD
Menu
SRTSSRTSHealthcare · Medical Devices

SRTS Stock Forecast: Sensus Healthcare, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.15
+0.96% on the day

The 4 Wall Street analysts covering Sensus Healthcare, Inc. hold a median 12-month price target of $5.75 — +82.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 11 Sept 2026 — in the upper half.

Market cap
$51.4M
Ticker Nerd rank
51 / 100
Median analyst target
$5.75
Analysts covering
4
Revenue$2.3M−68.7% y/y
Operating income−$3.2M
Net income−$8.7M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
+1.6%
YTD
−20.9%
1Y
−2.8%
From 52W high
−40.6%
From 52W low
+17.1%
$2.69
$5.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sensus Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Size
82
Volatility
80
Issuance
79
Value
44
Revisions
36
Momentum
35
Quality
32
Growth
20

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26SRTSHigh $6.00Median $5.75Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $4.00Median $5.75High $6.00

The green dot is the last close — the median target sits +82.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Lake StreetMaintainsBuy$4.50 → $4.00
17 Feb 2026Maxim GroupMaintainsBuy$8.00 → $6.00
17 Feb 2026Maxim GroupMaintainsBuy—
12 Aug 2025HC Wainwright & Co.MaintainsBuy—
8 Aug 2025Lake StreetMaintainsBuy—
19 May 2025Maxim GroupMaintainsBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025Lake StreetMaintainsBuy—
10 Feb 2025HC Wainwright & Co.MaintainsBuy—
18 Nov 2024HC Wainwright & Co.MaintainsBuy—
15 Nov 2024Maxim GroupMaintainsBuy—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.MaintainsBuy—
10 May 2024Maxim GroupMaintainsBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.MaintainsBuy—
4 May 2023Alliance Global PartnersMaintainsBuy—
4 May 2023HC Wainwright & Co.ReiteratesBuy—
10 Feb 2023Alliance Global PartnersMaintainsBuy—
10 Feb 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SRTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Sensus Healthcare, Inc. returned −2.8% against +17.5% for the S&P 500, dividends included.

SRTS vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26SRTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Sensus Healthcare, Inc. (SRTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
49.5×

Cheaper than 14% of US stocks

Price / sales
2.9×

Cheaper than 42% of US stocks

Price / book
1.4×

Cheaper than 59% of US stocks

EV / EBITDA
−2.8×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−68.7%

Higher than 4% of US stocks

Earnings growth (YoY)
−68.7%

Higher than 6% of US stocks

Gross margin
33.6%

Higher than 40% of US stocks

Operating margin
−138.9%

Higher than 12% of US stocks

Net margin
−88.4%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−34.8%

Higher than 26% of US stocks

Return on assets
−16.5%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sensus Healthcare, Inc. (SRTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sensus Healthcare, Inc. has a market value of $51.4M and an enterprise value of $36.5M.

  • Revenue in the twelve months to 30 June 2026: $17.5M. The latest quarter shrank 68.7% year on year.

  • Net income over the same four quarters: −$15.5M, a −88.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.94.

  • Free cash flow in the twelve months to 30 June 2026: −$7.0M.

  • Sensus Healthcare, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 16.5M.

  • Trailing P/E: 49.5×; forward P/E: −18.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sensus Healthcare, Inc. employs 60 people — $292K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SRTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SRTSSensus Healthcare, Inc.$51.4M
51
MYOMyomo, Inc.$51.5M
53
MDAISpectral AI, Inc.$49.1M
15
XTNTXtant Medical Holdings, Inc.$48.5M
72
NNOXNano-X Imaging Ltd.$56.9M
19
COCHEnvoy Medical, Inc.$56.9M
34
BDMDBaird Medical Investment Holdings Ltd.$46.4M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sensus Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRTS news & analysis

Sensus Healthcare Q2 Earnings Call Highlights

MarketBeat · 14 Aug 2026negative

Sensus Healthcare reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier. The decline was attributed to delayed third-party financing that prevented the company from recognizing revenue tied to eight equipment units before the end of June.

Why it matters — A SRTS watcher would care because the significant year-over-year revenue drop stems from a timing issue in financing and revenue recognition rather than necessarily lost demand, which directly affects the company's reported quarterly financials.

Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Sensus Healthcare, Inc. (SRTS). The item is a record of the company's quarterly earnings conference call and provides a transcript of management's discussion.

Why it matters — A SRTS watcher would care because the earnings call transcript offers direct insight into the company's quarterly results and management commentary.

Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights

Business Wire · 13 Aug 2026negative

Sensus Healthcare, Inc. (Nasdaq: SRTS) announced its financial results and business highlights for the three months ended June 30, 2026. Revenues were $2.3 million for the quarter, a decrease of $5.0 million from the 2025 quarter, driven by a lower number of units sold.

Why it matters — SRTS watchers would note a significant year-over-year revenue decline in the company's latest reported quarter, which underscores a drop in unit sales for its medical device treatments.

Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026

Business Wire · 30 July 2026neutral

Sensus Healthcare announced it will report its second quarter 2026 financial results on August 13, 2026, and management will hold a conference call that day at 4:30 pm Eastern time to review the results and provide a business update.

Why it matters — The announcement signals when SRTS shareholders can expect the company's next quarterly performance update and management commentary on its business outlook.

FAQ

Frequently asked questions about SRTS stock

What is the SRTS stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Sensus Healthcare, Inc. have a median 12-month price target of $5.75, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRTS stock a buy right now?

Of the 4 analysts covering Sensus Healthcare, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sensus Healthcare, Inc. 51 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRTS?

As at 11 Sept 2026, Sensus Healthcare, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will SRTS stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +82.5% from the last close, and Ticker Nerd's factor model ranks Sensus Healthcare, Inc. 51 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRTS stock forecast for 2030?

No analyst covering Sensus Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has SRTS stock performed over the past year?

Sensus Healthcare, Inc. returned -2.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sensus Healthcare, Inc. do?

Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological skin conditions.

What is the latest news on SRTS?

The most recent item we track (MarketBeat, 14 Aug 2026): "Sensus Healthcare Q2 Earnings Call Highlights". Sensus Healthcare reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier. The decline was attributed to delayed third-party financing that prevented the company from recognizing revenue tied to eight equipment units before the end of June.

Company

About Sensus Healthcare, Inc.

Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological skin conditions. The company develops and commercializes superficial radiation therapy systems that use low-energy X-ray technology to treat conditions such as non-melanoma skin cancers and keloids. Its product portfolio includes the SRT-100, SRT-100+, and SRT-100 Vision systems, along with related service and support offerings for healthcare providers. Sensus Healthcare serves dermatology and other clinical practices that seek targeted treatment options for superficial skin lesions and scar management. Based in Boca Raton, Florida, the company operates in the medical technology market with a focus on specialized radiation-based solutions for skin care applications.

CEO Mr. Joseph C. Sardano · 60 employees · United States · https://sensushealthcare.com